Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19443027 | 0.88 | PER2 (0.36) | PIK3CDPOLBPER2 | |
| SCHEMBL23790356 | 0.82 | PIK3CD (0.31) | PIK3CDPER2 | |
| SCHEMBL18792809 | 0.81 | PIK3CD (0.32) | PIK3CDPOLBALDH1A1 | |
| SCHEMBL18643112 | 0.80 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL24335867 | 0.80 | PKM (0.30) | PIK3CD | |
| SCHEMBL596921 | 0.78 | PER2 (0.38) | PIK3CDPER2ALDH1A1 | |
| SCHEMBL611663 | 0.78 | POLB (0.35) | PIK3CDPOLB | |
| SCHEMBL21690604 | 0.75 | — | — | |
| SCHEMBL21325293 | 0.74 | — | — | |
| SCHEMBL27423373 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | OCUTERRA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685737-B2 | Fluorinated integrin antagonists | OCUTERRA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230129394-A1 | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS | FELIQS CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20190225609-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FELIQS CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10301307-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | SCIFLUOR LIFE SCIENCES, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190040073-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | SCIFLUOR LIFE SCIENCES, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20170313708-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | FELIQS CORPORATION (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9790222-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| US-7968579-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2011-06-28 | — | — | US | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685737-B2 | Fluorinated integrin antagonists | ITGB5, ITGB1, ITGA5 | PIK3CD 1173/4885POLB 4045/4885PER2 4158/4885 |
| US-20230129394-A1 | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGA1 | PIK3CD 3632/4885POLB 1997/4885PER2 3451/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | PIK3CD 653/4885POLB 1904/4885PER2 3262/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | PIK3CD 1372/4885POLB 4819/4885PER2 1231/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885POLB 2088/4885PER2 4086/4885 |
| US-10301307-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | FFAR3, FFAR2, FFAR1 | PIK3CD 2051/4885POLB 4210/4885PER2 3422/4885 |
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | FFAR3, FFAR2, FFAR1 | PIK3CD 2051/4885POLB 4210/4885PER2 3422/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | PIK3CD 3717/4885POLB 453/4885PER2 2554/4885 |
| US-20190040073-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | PIK3CD 1552/4885POLB 4074/4885PER2 4511/4885 |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | MERTK, DAPK1, AXL | PIK3CD 653/4885POLB 1904/4885PER2 3262/4885 |
| US-20190225609-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | PIK3CD 2051/4885POLB 4210/4885PER2 3422/4885 |
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | PIK3CD 1454/4885POLB 937/4885PER2 1752/4885 |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | PIK3CD 451/4885POLB 332/4885PER2 1790/4885 |
| US-20170313708-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | PIK3CD 1552/4885POLB 4074/4885PER2 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.